Pancreatic Cancer Research

ResearcherUniversity of FreiburgActive in the last 2 years

Uwe A. Wittel

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-6194-2374; OpenAlex author ID A5047423734. Sources: OpenAlex.

Their work

Papers
29 (first author 0, last author 7)
Trials
0
Grants
0
Labs led
1
Collaborators
96
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 3 papers · 2020: 3 papers · 2021: 4 papers · 2022: 1 paper · 2023: 2 papers · 2024: 1 paper · 2025: 3 papers · 2026: 2 papers

Papers 29

  1. Vertical RAS pathway inhibition in pancreatic cancer drives therapeutically exploitable mitochondrial alterations. Co-author DOI 10.1038/s41392-025-02563-7↗
  2. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  3. The distance to arteries predicts the oncological outcome in pancreatic cancer surgery - results from a 3D reconstruction model. Last author DOI 10.1016/j.pan.2025.09.024↗
  4. Validation of two plasma multimetabolite signatures for patients at risk of or with suspected pancreatic ductal adenocarcinoma (METAPAC): a prospective, multic… Co-author DOI 10.1016/s2468-1253(25)00056-1↗
  5. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  6. Integrated Analysis of Cell-Free DNA and Novel Protein Biomarkers for Stratification and Therapy Monitoring in Stage IV Pancreatic Cancer: A Preliminary Study. Co-author DOI 10.3390/diagnostics15010049↗
  7. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  8. Surgical pancreatic biopsies for cases with locally advanced pancreatic cancer with inconclusive histology after interventional biopsy. Last author DOI 10.1016/j.sopen.2023.07.003↗
  9. Biomarkers in Liquid Biopsies for Prediction of Early Liver Metastases in Pancreatic Cancer. Co-author DOI 10.3390/cancers14194605↗
  10. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  11. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-021-86779-x↗
  12. Perioperative cell-free mutant KRAS dynamics in patients with pancreatic cancer Last author DOI 10.1093/bjs/znaa116↗
  13. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer. Co-author DOI 10.1186/s12885-020-07736-x↗
  14. Elevating pancreatic cystic lesion stratification: Current and future pancreatic cancer biomarker(s). Co-author DOI 10.1016/j.bbcan.2019.188318↗
  15. Metabolic Profiling of Early and Late Recurrent Pancreatic Ductal Adenocarcinoma Using Patient-Derived Organoid Cultures. Last author DOI 10.3390/cancers12061440↗
  16. Metabolic Adaptation during nab-Paclitaxel Resistance in Pancreatic Cancer Cell Lines. Co-author DOI 10.3390/cells9051251↗
  17. Unraveling altered RNA metabolism in pancreatic cancer cells by liquid-chromatography coupling to ion mobility mass spectrometry. Co-author DOI 10.1007/s00216-019-01814-1↗
  18. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. Co-author DOI 10.1186/s12885-019-6148-5↗
  19. Adjuvant chemotherapy after surgery for pancreatic ductal adenocarcinoma: retrospective real-life data. Last author DOI 10.1186/s12957-019-1732-3↗
  20. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  21. Identification and Validation of a Diagnostic and Prognostic Multi-Gene Biomarker Panel for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fgene.2018.00108↗
  22. Stereotactic body radiotherapy (SBRT) in recurrent or oligometastatic pancreatic cancer : A toxicity review of simultaneous integrated protection (SIP) versus … Co-author DOI 10.1007/s00066-017-1099-8↗
  23. The Role of Fibroblasts in Pancreatic Cancer: Extracellular Matrix Versus Paracrine Factors. Co-author DOI 10.1016/j.tranon.2017.04.009↗
  24. Prognostic factors after pancreatoduodenectomy with en bloc portal venous resection for pancreatic cancer. Co-author DOI 10.1007/s00423-015-1363-2↗
  25. Inducing a humoral immune response to pancreatic cancer antigen. Last author DOI 10.1016/j.cellimm.2016.09.002↗
  26. The prognostic influence of intrapancreatic tumor location on survival after resection of pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s12893-015-0110-5↗
  27. Potentials of plasma NGAL and MIC-1 as biomarker(s) in the diagnosis of lethal pancreatic cancer. Co-author DOI 10.1371/journal.pone.0055171↗
  28. The pathobiological impact of cigarette smoke on pancreatic cancer development (review). Co-author DOI 10.3892/ijo.2012.1414↗
  29. Pathobiological implications of MUC16 expression in pancreatic cancer. Co-author DOI 10.1371/journal.pone.0026839↗

Closest collaborators

The 25 strongest of 96 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Saskia Hussung · 6 shared papers, 2018–2024 · strength 0.85
  2. Ralph Fritsch · 6 shared papers, 2018–2024 · strength 0.85
  3. Melanie Boerries · 5 shared papers, 2018–2026 · strength 0.79
  4. Waldemar H. Uhl · 6 shared papers, 2018–2026 · strength 0.76
  5. Anke Reinacher‐Schick · 6 shared papers, 2018–2026 · strength 0.76
  6. Michael B. Ghadimi · 5 shared papers, 2019–2026 · strength 0.70
  7. Sophia Chikhladze · 4 shared papers, 2015–2025 · strength 0.67
  8. Dietrich Alexander Ruess · 4 shared papers, 2015–2026 · strength 0.66
  9. Andrea Tannapfel · 4 shared papers, 2018–2026 · strength 0.59
  10. Dorota Łubgan · 4 shared papers, 2019–2026 · strength 0.58
  11. Henriette Golcher · 4 shared papers, 2019–2026 · strength 0.58
  12. Robert Grützmann · 4 shared papers, 2019–2026 · strength 0.58
  13. Helmut Oettle · 4 shared papers, 2019–2026 · strength 0.58
  14. Sabine Semrau · 3 shared papers, 2021–2026 · strength 0.50
  15. Rainer Fietkau · 3 shared papers, 2021–2026 · strength 0.50
  16. Stefan Hubert Boeck · 3 shared papers, 2021–2026 · strength 0.50
  17. Lukas M. Braun · 4 shared papers, 2019–2021 · strength 0.49
  18. Markus Hecht · 2 shared papers, 2025–2026 · strength 0.40
  19. Dirk Waldschmidt · 2 shared papers, 2025–2026 · strength 0.40
  20. Bernd Kammerer · 3 shared papers, 2019–2020 · strength 0.36
  21. Simon Lagies · 3 shared papers, 2019–2020 · strength 0.36
  22. Carola Focke · 1 shared paper, 2025 · strength 0.27
  23. Julian Hipp · 2 shared papers, 2021 · strength 0.26
  24. Laura Klösges · 1 shared paper, 2023 · strength 0.24
  25. Friederike Inga Nollmann · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.